Herpes News and Research

RSS

Herpes is an infection caused by two different but closely related viruses — herpes simplex virus type 1 (HSV-1) or cold sores and herpes simplex virus type 2 (HSV-2) or genital herpes. Both are easy to catch. They have similar symptoms (blisters or sores) and both can occur on different parts of the body. When the infection is on the mouth, it is called oral herpes. When it is on or near the sex organs, it is called genital herpes. There is no cure for herpes. Treatments are available to speed up the healing of the genital sores.

New study reveals the genetic mechanism behind severe staphylococcal infections

A common culprit of skin and respiratory infections, Staphylococcus aureus is highly unpredictable. Between 20 and 30 percent of people carry quiet colonies on their skin and in their nostrils, which seldom cause problems beyond the occasional rash.

19 May 2022

Broad-spectrum polymeric antivirals against SARS-CoV-2

In a recent study published in the journal Advanced Science, researchers evaluated the potential and applicability of macromolecular viral inhibitors against respiratory viral pathogens.

17 May 2022

Scientists examine the impact of herpesviruses on (pre)diabetes

Scientists have recently analyzed the association between herpesviruses and type 2 diabetes. This study is available in the journal Diabetologia.

15 May 2022

Study explores macromolecular viral entry inhibitors as broad-spectrum first-line antivirals with anti-SARS-CoV-2 activities

Researchers created polystyrene sulfonate with significantly different molar masses, constructed these polymers as an exterior around spherical gold nanoparticles of various sizes to improve multivalency effects, measured antiviral effects of the antivirals on numerous viruses in vitro, and investigated the method of interaction of the leads with SARS-CoV-2 and lentiviral particles.

13 May 2022

Exploring simultaneous and sequential COVID-19 vaccine candidate

Researchers developed novel lipid nanoparticle (LNP)-based messenger ribonucleic acid vaccine formulations against three pathogenic coronaviruses.

10 May 2022

NIH launches clinical study to evaluate an investigational preventative vaccine for Epstein-Barr virus

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial to evaluate an investigational preventative vaccine for Epstein-Barr virus (EBV).

6 May 2022

New technique can accurately detect viruses in tumors from clinical next-generation sequencing

Researchers have developed a method to accurately detect viruses from clinical next-generation sequencing and describe novel associations between specific tumors and viruses that warrant further investigation.

5 May 2022

Viral microRNA acts as a master regulator to induce the reactivation of dormant herpesviruses

Dormant herpesviruses induce their reactivation via a previously unknown cellular mechanism mediated by a viral microRNA. Würzburg researchers show this in the journal "Nature".

5 May 2022

Studying immunomodulatory effects of microbiota helps design prophylactic and therapeutic interventions against COVID-19

Researchers reviewed the potential clinically relevant mechanisms by which microbiota and microbiota-derived metabolites influence the host immune responses to SARS-CoV-2 infection.

3 May 2022

Exploring oncolytic viral therapeutics and immunotherapies derived from DNA and RNA

A new review initially described the developments in cancer-based medicines that included vaccinations, vector-based techniques, and genome injection using DNA and RNA-based nucleic acid therapeutics.

28 Apr 2022

Green tea catechin as pan-coronavirus attachment inhibitor

In a recent study posted to the Research Square* preprint server, researchers assessed the impact of green tea catechin epigallocatechin gallate (EGCG) on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

27 Apr 2022

St. John's wort extract shows potent antiviral activity against SARS-CoV-2 and its variants

Scientists from Germany have recently identified Hypericum perforatum, a widespread herbal plant known as St. John's wort, as a potential antiviral agent against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The study is published in the journal Pharmaceuticals.

27 Apr 2022

Herpes News and Research

Further Reading

New study reveals the genetic mechanism behind severe staphylococcal infections

Broad-spectrum polymeric antivirals against SARS-CoV-2

Scientists examine the impact of herpesviruses on (pre)diabetes

Study explores macromolecular viral entry inhibitors as broad-spectrum first-line antivirals with anti-SARS-CoV-2 activities

Exploring simultaneous and sequential COVID-19 vaccine candidate

NIH launches clinical study to evaluate an investigational preventative vaccine for Epstein-Barr virus

New technique can accurately detect viruses in tumors from clinical next-generation sequencing

Viral microRNA acts as a master regulator to induce the reactivation of dormant herpesviruses

Studying immunomodulatory effects of microbiota helps design prophylactic and therapeutic interventions against COVID-19

Exploring oncolytic viral therapeutics and immunotherapies derived from DNA and RNA

Green tea catechin as pan-coronavirus attachment inhibitor

St. John's wort extract shows potent antiviral activity against SARS-CoV-2 and its variants

The brain's reaction to COVID's inflammatory tidal wave

Study shows that the SARS-CoV-2 envelope protein potently restricts HIV-1 infection

Algae found to inhibit SARS-CoV-2 infection in vitro

Study evaluates the prevalence of autoantibodies targeting type I interferons in critically-ill COVID-19 patients

Study shows BCG vaccine provides no protection against SARS-CoV-2 in mice and hamsters

Researchers receive $3.7 million to identify reasons for higher rates of cancers, other diseases in HIV patients

Understanding immune responses to SARS-CoV-2 infections in children

Study opens the door to a new approach to attacking herpesviruses

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News